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Abstract
While preventive methods for cervical cancer are effective, available therapies for advanced 
cervical cancers are ineffective. New experimental evidence points to weaknesses of prior studies 
and provides fresh molecular insights on the opposing roles of ERα and PR, which may be 
translated into valuable treatment for a subset of cervical cancers.
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Cervical Cancer and Human Papillomavirus
Cervical cancer is the fourth most frequent cancer and fourth leading cause of cancer death 
in women, worldwide. Cervical intraepithelial neoplasia (CIN) premalignant lesions precede 
cervical cancer. CINs (CIN1-CIN3) are effectively treated by simple surgeries, but they 
increase the risk for complications in future pregnancy. Current therapies for cervical cancer 
are ineffective for advanced or recurrent cervical cancer. Thus, the development of more 
effective therapy for cervical cancer and CIN is urgently needed.
High-risk human papillomavirus (HPV) is a major etiological factor and HPV vaccines 
reduce the likelihood of CIN and cervical cancer [1]. The HPV oncogenes E6 and E7 are 
necessary for HPV-induced cervical carcinogenesis. Persistent HPV infection is 
occasionally established when the immune system fails to resolve initial infections. CIN3 
develops only in 14-40% of women with persistent HPV infections, and the rate of 
progression from CIN3 to invasive cancer is approximately 30% in unscreened population, 
suggesting that CIN lesions can regress spontaneously [1-3]. Consequently, less than 0.1% 
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of HPV-infected women succumb to cervical cancer. Despite the oncogenic activities of E6 
and E7, primary rodent cells are transformed by high-risk HPV DNAs only in the presence 
of other factors such as a glucocorticoid or activated Ras [1]. Furthermore, cervical 
neoplastic diseases do not develop spontaneously in transgenic mice expressing E6 and E7 
[2]. These observations indicate that other factors, in addition to HPV, are required for 
cervical carcinogenesis.
This article focuses on the roles of the female sex hormones estradiol (E2) and progesterone 
(P4) in cervical carcinogenesis, and describes how their receptors and/or downstream gene 
products may be targets for therapy.
Female Hormones and Their Receptors in Cervical Cancer
Long-term oral contraceptives use or multiple parities increases the risk for cervical cancer 
in HPV-infected women [2]. Since most oral contraceptives contain E2 and synthetic P4, and 
high levels of E2 and P4 are maintained during pregnancy, these observations implicate the 
female hormones in cervical cancer. E2 and P4 bind to and activate the estrogen (ERα and 
ERβ) and progesterone (PR-A and PR-B) receptors, respectively, ligand-dependent 
transcription factors that play key roles in numerous processes, including cancer. ERβ 
expression in the cervix is undetectable [4]. Thus, the E2–ERα and P4–PR signaling 
pathway may be involved in the progression and/or development of cervical cancer. 
Although the association between E2 replacement or selective ER modulator (SERM) 
therapy and cervical cancer is controversial [2], recent animal model studies, discussed 
below, support an oncogenic role of E2–ERα in cervical cancer.
Epidemiological studies looking at associations between medroxyprogesterone acetate 
(synthetic P4) and cervical cancer have been inconclusive, because data have not been 
stratified based on HPV infection. Although the results need verification, one study indicates 
that the use of medroxyprogesterone acetate decreases the risk of high-grade CINs among 
HPV-infected women [5]. Expression levels of ERα and PR do not necessarily reflect their 
activities, which depend on hormone concentrations. In addition, the levels of female 
hormones and hormone receptors continuously change due to biological (menstrual cycle), 
behavioral (hormonal contraceptive use) and environmental factors (estrogenic chemicals). 
Therefore, it is challenging to gain insight on a role for ERα and PR using studies based on a 
single measure of these receptors. Biomarkers for ERα, PR-A and PR-B activity in the 
cervix should be developed. It is also difficult to evaluate the role of E2–ERα or P4–PR in 
cervical cancer from several published in vitro studies, because of non-physiologic hormone 
doses and use of cervical cancer cell lines (e.g., SiHa, CaSki and HeLa) that do not express 
the receptors [2]. Published clinical trials also are not informative because of short follow-up 
periods, poor drug choice or underpowered statistical analyses [2, 6].
Mouse Model of Cervical Cancer
The Role of E2–ERα
Transgenic mice expressing HPV16 E6 (K14E6) or E7 (K14E7) have been extensively 
characterized in the context of cervical cancer [2]. Consistent with the notion that HPV 
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alone is not sufficient, cervical cancer arises at high frequency only after chronic low-dose 
E2 treatment. The cervical diseases that arise in these mice recapitulate key aspects of 
human cervical cancer, including progressive development (CIN1, CIN2, CIN3 and cancer), 
cancer development in the transformation zone, and expression patterns of biomarkers 
similar to those of human malignancy [2]. In the HPV transgenic mice, ERα is necessary for 
cervical cancer development, and SERMs are efficient in treating the disease [2]. In the 
same mouse model, ablation of ERα expression in stromal cells results in complete 
regression of cervical neoplastic diseases [7], suggesting a paracrine mechanism. Since ERα 
is expressed in most cervical cancer stroma, this appears relevant to human cervical cancer 
[4, 8]. I speculate that ERα activates expression of secretory factors such as growth factors 
and cytokines in stromal cells that then activate oncogenic growth factor receptor signaling 
in neoplastic epithelial cells (Fig. 1). Identification of a growth factor receptor transmitting 
stromal ERα signal to epithelial cells would help the development of a targeted therapy for 
cervical cancer (Fig. 1). In this regard, amphiregulin—an epidermal growth factor receptor 
ligand—mediates paracrine effects of ERα during mammary gland development and 
carcinogenesis, and insulin-like growth factor 1 mediates E2-induced endometrial cell 
proliferation [9-11].
ERα expression is gradually lost in neoplastic epithelial cells as cervical neoplastic disease 
progresses [4, 12]. Knockdown of ERα enhances invasion of the chick chorioallantoic 
membrane by cervical cancer cells [12]. These observations raise the possibility that stromal 
ERα is oncogenic, whereas epithelial ERα has dual functions, oncogenic in early stages and 
tumor-suppressive in late stages of cervical carcinogenesis (Fig. 1). This model further 
implies that stromal E2–ERα signaling promotes ERα-negative cervical cancer. Using the 
Cre-lox technology and the HPV transgenic mouse model, disease stage-specific function of 
ERα can be addressed by temporal ablation of ERα expression in neoplastic epithelial cells.
The Role of P4–PR
The cervical neoplastic disease burden in K14E7/PR+/+ mice is similar to that in K14E7/
PR−/− mice [13]. This is as expected, since chronic E2 treatment inhibits the P4 surge (i.e., 
low P4 levels throughout a study period), and thus deletion of PR would have little effect 
(Fig. 2a). However, activation of PR by medroxyprogesterone acetate causes regression of 
CIN and cervical cancer in the HPV transgenic mouse model [13]. Based on these results, I 
hypothesize that PR acts as a ligand-dependent tumor suppressor in cervical cancer as in 
endometrial cancer [11]. While PR is expressed in 100% of cervical cancers arising in this 
mouse model, only 20-40% of human cervical cancers express PR [13, 14]. This difference 
may reflect hormonal status and/or other factors during neoplastic disease development. I 
speculate that PR− cancers are frequent in humans because women with high P4 levels are 
more common than those with persistently high E2 levels. Persistently high P4 levels or 
cyclic P4 surges may provide selective pressure for rare PR− cells (Fig. 2b-c); however, PR− 
cervical cancer would rarely occur when high P4 levels persist because ERα activity would 
be minimal due to continuously low E2 levels. Such selection would not occur under a 
persistent E2 stimulation condition (Fig. 2a). Cervical carcinogenesis would be highly 
efficient under this hormonal condition as shown in the HPV transgenic mouse model [2]. In 
this regard, it might be important to determine whether HPV-infected women who do not 
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have P4 surges are at higher risk (e.g., women with polycystic ovarian syndrome) for 
cervical cancer similar to endometrial cancer [11].
The results in the mouse model system suggest that proper use of ERα and PR ligands could 
be useful in the treatment of cervical cancer. If the cancer stroma expresses ERα, treatment 
with SERMs such as faslodex might be effective, regardless of expression of ERα in the 
cancer cells (Fig. 1). Co-treatment with SERMs and selective PR modulators (SPRMs) such 
as medroxyprogesterone acetate may be synergistic if both ERα and PR are expressed in 
appropriate cells.
Conclusions
Although there has been substantial improvement in our understanding of ERα and PR 
functions over the last decade, their function and mechanism in physiology and 
pathophysiology of the cervix is still underappreciated. Studies using the HPV transgenic 
mouse model have expanded understanding of the molecular pathogenesis of cervical 
cancer, and some of the underlying mechanisms that involve readily targetable hormone 
receptors. These advances support the hypothesis that epithelial P4–PR is tumor suppressive 
and that E2–ERα is oncogenic and tumor suppressive depending on cell types in which it 
functions. Next is to see if these findings are translatable to human disease via clinical trials 
evaluating the efficacy of SERMs and/or SPRMs in treating cervical cancer and CINs. As 
many of these classes of drugs are already in clinical use, the results could be translated 
quickly to clinical application, whereas further understanding of ERα and PR functions in 
cervical carcinogenesis will reveal new therapeutic targets for the disease.
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Figure 1. A proposed model of ERα mechanism in cervical cancer
A gene(s) denoted as X that encodes for a secretory protein(s) is activated by ERα in 
stromal cells. The secretory protein activates a membrane receptor-mediated pathway in 
epithelial cells, which, in conjunction with E6 and E7, promotes initiation and progression 
of cervical cancer (CC). SERMs and receptor inhibitors could be effective in treating CC. It 
is proposed that E2-liganded ERα promotes the development of CIN, but the activated ERα 
in neoplastic epithelial cells inhibits further progression of CIN. BM, basement membrane.
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Figure 2. A model of the impact of the balance between E2 and P4 on cervical cancer
An E2 surge promotes epithelial cell proliferation in female reproductive tracts and a 
following P4 surge reverses it [2, 11]. While E2 surges activates ERα and increases PR 
expression in the cervix [7], the activity of PR remains minimal because P4 levels are low 
during E2 surges. PR activity is heightened and ERα activity decreases during the following 
P4 surge. As ERα and PR downregulate their own expression, their expression levels are 
lower when activated by the hormones. These regulations occur in both stroma and 
epithelium. A model of the impact of normal and impaired hormonal cycle on cervical 
cancer is proposed. Tumor-promotive E2 action is mainly through stromal ERα (see Fig. 1). 
Epithelial PR likely mediates, at least in part, tumor-suppressive function of P4 and thus 
high P4 has little effect on PR− cancer cells.
(a) Persistently high levels of E2 (high ERα activity) maintains low P4 levels (low PR 
activity). Under this hormonal condition, the development of PR+ cancers is more likely 
because there is no selective pressure for PR− cancers.
(b) Cancer development is unlikely under this hormonal condition because of persistently 
low ERα activity. If it occurs nonetheless, it is likely PR− cancer.
(c) E2 and P4 peak sequentially in turn and are never high concurrently during hormone 
cycle (left, luteal phase; right, proliferative phase). PR− cells have advantage to become 
cancerous.
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The thickness of arrows indicates the relative likelihood of an event. Note that HPV must be 
present in all three hormonal conditions for cancer development.
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